MedTrace Logo

Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

NCT02881853 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2017-07-11

No results posted yet for this study

Summary

This is a Phase 1b, combined multiple dose subcutaneous (SC) bioavailability (BA) and multiple ascending dose (MAD) study evaluating safety, tolerability and BA of SC XmAb7195 in healthy subjects and in subjects with atopic disease.

Conditions

  • Healthy Volunteers
  • Atopic Disease

Interventions

DRUG

XmAb7195

DRUG

Placebo

Sponsors & Collaborators

  • ICON Early Phase Services, LLC

    collaborator UNKNOWN

  • Xencor, Inc.

    lead INDUSTRY

Principal Investigators

  • Emanuel P DeNoia, MD · ICON Early Phase Services, LLC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-17
Primary Completion
2017-02-24
Completion
2017-02-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02881853 on ClinicalTrials.gov